Markus Müschen Selected Research

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Leukemia, Pre B Cell)

1/2017	Metabolic gatekeeper function of B-lymphoid transcription factors.
1/2017	Genetic analysis of Ikaros target genes and tumor suppressor function in BCR-ABL1+ pre-B ALL.
1/2017	B-cell identity as a metabolic barrier against malignant transformation.
4/2016	PTEN opposes negative selection and enables oncogenic transformation of pre-B cells.
1/2015	Mechanisms of pre-B-cell receptor checkpoint control and its oncogenic subversion in acute lymphoblastic leukemia.
3/2013	Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy.
1/2005	Tracing the pre-B to immature B cell transition in human leukemia cells reveals a coordinated sequence of primary and secondary IGK gene rearrangement, IGK deletion, and IGL gene rearrangement.
3/2004	The BCR-ABL1 kinase bypasses selection for the expression of a pre-B cell receptor in pre-B acute lymphoblastic leukemia cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Markus Müschen Research Topics

Disease

32	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2022 - 03/2004
32	Neoplasms (Cancer) 01/2022 - 03/2003
28	Leukemia 01/2022 - 03/2004
8	Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Leukemia, Pre B Cell) 01/2017 - 03/2004
6	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 06/2012 - 10/2007
4	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2022 - 03/2014
4	Philadelphia Chromosome 05/2015 - 05/2007
3	Autoimmune Diseases (Autoimmune Disease) 01/2022 - 01/2021
3	Residual Neoplasm 01/2020 - 08/2011
3	Lymphoma (Lymphomas) 01/2020 - 10/2007
3	B-Cell Lymphoma (Lymphoma, B Cell) 06/2015 - 08/2013
2	Myeloid Leukemia (Leukemia, Myelocytic) 01/2020 - 01/2017
2	Infections 12/2019 - 06/2003
2	Obesity 01/2017 - 10/2010
2	Blast Crisis (Blast Phase) 10/2010 - 09/2009
1	Glioblastoma (Glioblastoma Multiforme) 01/2021
1	B-Cell Leukemia (Leukemia, B Cell) 01/2020
1	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2019
1	Burkitt Lymphoma (Burkitt's Lymphoma) 01/2018
1	Hyperglycemia 01/2017
1	Breast Neoplasms (Breast Cancer) 08/2015
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 03/2014
1	Carcinoma (Carcinomatosis) 08/2013

Drug/Important Bio-Agent (IBA)

18	Phosphotransferases (Kinase)IBA 01/2022 - 03/2004
10	Pre-B Cell ReceptorsIBA 04/2016 - 03/2004
7	Proteins (Proteins, Gene)FDA Link 01/2020 - 12/2004
6	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 12/2008
6	Pharmaceutical PreparationsIBA 01/2020 - 08/2011
6	Imatinib Mesylate (Gleevec)FDA Link 01/2016 - 03/2004
5	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2016 - 08/2009
4	Biological ProductsIBA 10/2020 - 10/2010
4	Tyrosine Kinase InhibitorsIBA 01/2018 - 02/2010
3	AntibodiesIBA 01/2021 - 01/2018
3	Transcription Factors (Transcription Factor)IBA 01/2020 - 01/2005
3	Cytidine DeaminaseIBA 12/2019 - 05/2007
3	AntigensIBA 01/2019 - 06/2003
3	GlucocorticoidsIBA 01/2017 - 01/2017
2	Biomarkers (Surrogate Marker)IBA 01/2022 - 11/2012
2	ChromatinIBA 01/2021 - 01/2017
2	RNA (Ribonucleic Acid)IBA 01/2021 - 01/2020
2	Glucose (Dextrose)FDA LinkGeneric 01/2018 - 01/2017
2	ibrutinibIBA 01/2017 - 06/2015
2	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 04/2016 - 07/2014
2	venetoclaxIBA 12/2015 - 03/2014
2	CytokinesIBA 07/2015 - 01/2015
2	SurvivinIBA 04/2015 - 08/2011
2	Agammaglobulinaemia Tyrosine KinaseIBA 07/2014 - 09/2005
2	Peptides (Polypeptides)IBA 08/2013 - 10/2011
2	nilotinib FDA Link 03/2013 - 10/2007
2	Immunoglobulin Light Chains (Immunoglobulin Light Chain)IBA 10/2011 - 03/2004
2	src-Family KinasesIBA 03/2011 - 08/2009
2	bcr-abl Fusion ProteinsIBA 03/2011 - 10/2007
2	Antigen Receptors (Antigen Receptor)IBA 07/2004 - 03/2004
1	Interleukin-7 (Interleukin 7)IBA 01/2022
1	6-methyladenineIBA 01/2021
1	isocitric acid (isocitrate)IBA 01/2021
1	Oxidoreductases (Dehydrogenase)IBA 01/2021
1	UbiquitinIBA 01/2021
1	Calcibiotic Root Canal SealerIBA 10/2020
1	N-methyladenosineIBA 01/2020
1	Green Fluorescent ProteinsIBA 01/2020
1	A-Form DNA (A-DNA)IBA 01/2020
1	IntegrinsIBA 01/2020
1	Alpha-Ketoglutarate-Dependent Dioxygenase FTOIBA 01/2020
1	N,N-dimethylarginine (asymmetric dimethylarginine)IBA 10/2019
1	Histones (Histone)IBA 10/2019
1	B-Cell Activation Factor ReceptorIBA 01/2019
1	CD19 AntigensIBA 01/2019
1	SOXC Transcription FactorsIBA 01/2019
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 12/2018
1	Threonine (L-Threonine)FDA Link 01/2018
1	Membrane Proteins (Integral Membrane Proteins)IBA 01/2018
1	Protein Phosphatase 2 (Protein Phosphatase 2A)IBA 01/2018
1	CarbonIBA 01/2018
1	Serine (L-Serine)FDA Link 01/2018
1	Valosin Containing ProteinIBA 10/2017
1	EnzymesIBA 01/2017
1	Dexamethasone (Maxidex)FDA LinkGeneric 01/2017
1	Dasatinib (BMS 354825)FDA Link 01/2017
1	STAT5 Transcription FactorIBA 01/2017
1	Adenosine Triphosphate (ATP)IBA 01/2017
1	Mercaptopurine (6 Mercaptopurine)FDA LinkGeneric 01/2017
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 04/2016
1	TensinsIBA 04/2016
1	Proto-Oncogene Proteins c-akt (Protein Kinase B)IBA 04/2016
1	ponatinibIBA 01/2016
1	idelalisibIBA 06/2015
1	sepantroniumIBA 04/2015
1	Long Noncoding RNAIBA 10/2014
1	EpitopesIBA 07/2014
1	Syk KinaseIBA 07/2014
1	tyrosine receptor (receptor, tyrosine)IBA 07/2014
1	Phenylalanine (L-Phenylalanine)FDA Link 08/2013
1	AcetylesteraseIBA 04/2013
1	N-Acetylneuraminic Acid (Sialic Acid)IBA 04/2013
1	Natalizumab (Tysabri)FDA Link 03/2013

Therapy/Procedure

13	Therapeutics 01/2021 - 07/2004
7	Drug Therapy (Chemotherapy) 11/2021 - 08/2011
1	Heterologous Transplantation (Xenotransplantation) 01/2020
1	Combination Drug Therapy (Combination Chemotherapy) 01/2017